Skip to main content
Premium Trial:

Request an Annual Quote

Serenex in Chemoproteomics Deal with GSK

NEW YORK, May 5 - Serenex said today that GlaxoSmithKline would use its chemoproteomics technology in select drug discovery programs.

 

GSK will have access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against thousands of protein targets simultaneously.

 

According to Serenex, the companies will evaluate how these technologies impact the lead identification process.

 

Financial terms of the agreement were not provided.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.